An additional literature survey also revealed that leucine is an inhibitor of a peptide hydrolase, dipeptidyl-peptidase IV (DPP IV) [22], and that DPP IV is a target of inhibitor compounds for type 2 diabetes therapy [23]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.